We are pleased to announce that on April 24^th,TECVAYLI (teclistamab) was recommended for reimbursement by the pan-Canadian Oncology Drug Review Expert Review Committee (pERC) of Canada’s Drug Agency (CDA-AMC)*– the first bispecific antibody for myeloma to be recommended for funding in Canada.  

The pERC’s final decision states that contingent on a price reduction, teclistamab should be funded for adults with relapsed/refractory myeloma who: have received at least 3 lines of therapy, including a proteasome inhibitor (PI), immunomodulatory drug (IMiD), anti-CD38 monoclonal antibody (mAb), and who meet additional conditions listed in the report (p5).  

The recommendation won’t immediately allow Canadians to access funding for TECVAYI— price negotiations must first be completed. Yet this remains an important step towards improving access to new myeloma treatments in Canada.  

*On May 1^st the Canadian Association for Drugs and Technologies in Health (CADTH) became Canada’s Drug Agency (CDA-AMC). CDA-AMC recommendations do not apply to Quebec.